Delay in the Provision of Antiretroviral Therapy to HIV-infected TB Patients in Nigeria

B. Odume¹, I. Pathmanathan², S. Pals², K. Dokubo², D. Onotu¹, O. Obinna¹, D. Anand², J Okuma³, E. Okpokoro³, S. Dutt³, E. Ekong³, N. Chukwurah⁴, P. Dakum³, and H. Tomlinson¹

¹Division of Global HIV and TB, US Centers for Disease Control and Prevention, Nigeria
²Division of Global HIV and TB, US Centers for Disease Control and Prevention, USA
³Institute of Human Virology, Nigeria
⁴National Tuberculosis and Leprosy Control Program, Federal Ministry of Health, Nigeria

Abstract

Background—Nigeria has a high burden of HIV and tuberculosis (TB). To reduce TB-associated morbidity and mortality, the World Health Organization recommends that HIV-positive TB patients receive antiretroviral therapy (ART) within eight weeks of TB treatment initiation, or within two weeks if profoundly immunosuppressed (CD4<50 cell/μL).

Methods—TB and HIV clinical records from facilities in two Nigerian states between October 1st, 2012 and September 30th, 2013 were retrospectively reviewed to assess uptake and timing of ART initiation among HIV-positive TB patients. Healthcare workers were qualitatively interviewed to assess TB/HIV knowledge and barriers to timely ART.

Results—Data were abstracted from 4,810 TB patient records, of which 1,249 (26.0%) had HIV-positive or unknown HIV status documented, and the 574 (45.9%) HIV-positive TB patients were evaluated for timing of ART uptake relative to TB treatment. Among 484 (84.3%) HIV-positive TB patients not already on ART, 256 (52.9%, 95% CI: 45.0–60.8) were not initiated on ART during six months of TB treatment. 30.0% of 273 patients with a known CD4≥50cells/μL started ART within eight weeks, and 14.8% of 54 patients with a known CD4<50cells/μL started within the recommended two weeks. Only 42% of health workers interviewed reported knowing to interpret guidelines on when to initiate ART in HIV-positive TB patients based on CD4 cell count results. CD4 cell count significantly predicted timely ART uptake.

Conclusion—A large proportion of HIV-positive TB patients were not initiated on ART early or even at all during TB treatment. Retraining of staff, and interventions to strengthen referral

Authors agree that this article remains permanently open access under the terms of the Creative Commons Attribution License 4.0 International License

Author Contributions
A.D., K.D. and B.O. conceived and designed the study; B.O., K.D., A.D., O.O., D.O., N.C. and S.D. developed the study tools and protocol; B.O., I.P., O.O., S.D., E.O and, E.E. trained research assistants and supervised data collection; S.P., J.O. and E.O. analyzed the data; B.O., I.P and S.P. drafted and edited the paper and K.D., S.P., A.D., D.O., O.O., J.O., E.O., D.S., E.E., N.C., P.D. and H.T. reviewed the paper.

Conflicts of Interest
We report no conflicts of interest to disclose.
systems should be implemented to ensure timely provision of ART among HIV-positive TB patients in Nigeria.

Keywords
Tuberculosis; HIV; Tuberculosis and HIV co-infection; Anti-retroviral Therapy; DOTS

1. Introduction

Tuberculosis (TB) and HIV are the two leading causes of death from infectious diseases in resource-limited countries [1]. The HIV epidemic has led to a major upsurge in TB cases worldwide, especially in Africa, as people living with HIV (PLHIV) who are infected with TB are much more likely to develop TB disease than those who are HIV-negative. Nigeria, in particular, has about 3.5 million PLHIV, an HIV prevalence of 3.1% among adults aged 15–49 years, and the highest number of AIDS-related deaths in the world [2]. In addition, in 2015 the World Health Organization (WHO) ranked it among the six countries that contribute 60% of the world’s TB burden [1]. The same year, the HIV positivity rate among TB patients with a documented HIV test result was 17% [1].

The updated 2012 WHO strategic framework for TB/HIV collaborative activities highlights specific activities to reduce HIV-associated TB, including intensified TB case finding, isoniazid preventive therapy and TB infection control for PLHIV, as well as provider initiated HIV counseling and testing for TB patients, with early antiretroviral therapy (ART) uptake for co-infected patients [3]. Several clinical trials have demonstrated survival benefit due to early initiation of ART among HIV-infected patients with TB, particularly among those with very low CD4 cell counts [4–8]. Based on this evidence, WHO guidelines recommend that all HIV-positive TB patients receive ART within eight weeks of TB treatment initiation, or within two weeks if profoundly immunosuppressed (CD4<50cell/μL) [3].

In Nigeria, there has been remarkable progress in the implementation of collaborative TB/HIV activities over the past few years. Guidelines published by the national TB/HIV technical working group of the Federal Ministry of Health (FMOH) prescribed the initiation of all TB/HIV patients on ART, irrespective of CD4 cell count, with timing in line with WHO recommendations [9].

This study aimed to assess uptake of ART among HIV-positive TB patients in Nigeria, the timing of ART initiation in relation to TB treatment, and TB treatment outcomes of co-infected patients. Through in-depth interviews provider perceptions and current practices of patient referral systems were also ascertained. Findings will assist the FMOH and President’s Emergency Plan for AIDS Relief (PEPFAR)-funded implementing partners to develop effective interventions to improve access to and quality of TB/HIV care and treatment services in Nigeria. They also establish a baseline for monitoring future progress of TB/HIV programme implementation.
2. Methods

Study Design and Sampling

This evaluation involved a retrospective review of TB and HIV clinical records for adult TB patients aged 15 years and above who enrolled in all TB Directly Observed Therapy (DOT) facilities in Federal Capital Territory (FCT) and Ogun State between October 1, 2012 and September 30, 2013. Health facility TB registers and additional supplemental TB data sources such as Presumptive TB registers, TB treatment cards, and Local Government Area TB registers were reviewed to determine the total number of TB patients seen in 2013 with an HIV status recorded as positive or unknown. These patients were traced to HIV facilities to ascertain their treatment status and timing of ART initiation relative to TB treatment, using HIV care cards and ART registers. In both states, all PEPFAR-supported ART treatment facilities that were providing ART services as of October 1, 2012 were included. In FCT there were 16 facilities and in Ogun State there were 28.

In-depth interviews were conducted with 333 key health care workers selected randomly across all the study facilities using a semi-structured questionnaire, in order to assess knowledge and practices related to TB/HIV management as well as provider perceptions about the barriers to provision and uptake of ART.

Data Collection and Analysis

Data were collected using a specifically designed data abstraction form that captured demographics, TB and HIV treatment, timing of ART, and TB treatment outcome information, following a retrospective review of the existing TB and HIV clinical and program recording and reporting systems. Descriptive statistics, including frequencies and percentages were used to summarize the data, and 95% confidence limits for all statistics were computed, taking into account the design effect resulting from within-clinic correlation. Unadjusted and adjusted odds ratios (ORs and AORs) and 95% confidence intervals (CI) were calculated to describe associations between categorical variables and ART uptake. Multiple logistic regression was used to assess for predictors of timely ART uptake. We defined ‘timely ART’ per WHO guidelines as ART started within two weeks of TB treatment initiation for patients with a CD4 cell count <500 cells/μL, and within eight weeks for all other cases. For the purposes of the multivariate analysis, we also considered ART initiation to have been timely for patients with a missing CD4 cell count only if it was started within two weeks, presuming that in the absence of a CD4 test the patient should be treated sooner rather than later. SAS 9.3® (SAS Institute, Cary, NC) was used with procedures designed to account for clustered data, such as PROC SURVEYFREQ and PROC SURVEYLOGISTIC. The in-depth interviews were transcribed, coded, and thematically analyzed.

Ethical Considerations

The protocol and all supporting data collection tools were reviewed by the United States Centers for Disease Control and Prevention (CDC) Associate Director for Science and the Nigeria Research and Ethics Committee, and was determined as a non-research program.
evaluation as the study involved the use of routine programmatic data with minimal risk to subjects.

3. Results

Baseline Characteristics of Study Participants

Data were abstracted from a total of 4,810 TB patients from 44 DOTS sites in FCT and 70 in Ogun State. These were made up of 1,249 TB patients with a positive or unknown HIV status (574 and 675, respectively). Of the HIV-positive TB patients, median age was 36 (interquartile range [IQR] 30–43), 308 (54.1%) were female, and median CD4 cell count was 178 cells/μL (IQR: 80–298) (Table 1). Most of these patients were between ages 25–44 (69.5%), and seen within secondary health care facilities (55.7%). Three hundred and fifty-one (65.9%) accessed DOT at health facilities while 182 (34.2%) had TB treatment supporters for treatment at home. Two hundred and forty six (44.7%) had pulmonary smear-positive TB, 277 (50.4%) had pulmonary smear-negative TB, and 27 (4.9%) had extra-pulmonary TB. The majority of patients were new TB cases (92.9%) (Table 1).

Timing of ART Uptake among TB/HIV Co-infected Patients

Among 574 HIV-positive TB patients evaluated, 90 (15.7%, 95% CI: 7.1–24.2) had already started ART before TB treatment, while 256 (44.6%, 95% CI: 35.9–53.3) were not documented to have initiated on ART during the six-month course of TB treatment at all. CD4 cell count was missing for 199 patients (34.7%). Of the 273 patients with a known CD4 cell count greater than or equal to 50 cells/μL who were not already on ART when they started TB treatment, 82 (30.0%, 95% CI: 22.4–37.7) started ART within the recommended eight weeks of TB treatment initiation, while 60 (22.0%, 95% CI: 12.4–31.5) started ART during TB treatment but only after eight weeks. Among the 54 patients with a CD4 cell count <50 cells/μL who were not already on ART at the time of TB treatment initiation, only eight (14.8%, 95% CI: 6.6–23.0) commenced ART within the recommended two weeks of TB treatment initiation, and 21 others (38.9%) started ART, but after two weeks had passed. The remaining 25 (46.3%) were not documented to have started ART at all while on TB treatment (Table 2). Of these 25, 14 achieved TB cure or treatment completion, three defaulted, three died, four transferred out and one had no TB treatment outcome reported.

Factors Associated with Timely ART Uptake among Co-infected Patients

In our multivariate analysis, CD4 cell count was found to be the only factor associated with Timely ART provision (using the previously stated definition of “timely ART provision”), with AORs of 2.7 (95% CI: 1.4–5.3) and 2.7 (95% CI: 1.2–6.2) for CD4 cell count categories 50–199 cells/μL and 200–499 cells/μL, respectively, when compared with having a CD4 cell count less than 50 cells/μL (Table 3).

TB Treatment Outcomes for HIV-Positive Patients

TB treatment outcome was documented for 558 (97.4%) of patients with a positive HIV status (Table 1). Seventy eight percent of patients with a CD4 cell count ≥50 cells/μL had documented cure or treatment completion (a positive outcome), compared with 63.2% of those with CD4 cell count <50 cells/μL and 57.2% of those with a missing CD4 cell count.
Removing the 41 patients who transferred out, the odds of a positive outcome for patients with a CD4 cell count ≥50 cells/μL was 2.6 (95% CI: 1.6–4.3) times that for patients with a missing CD4 cell count, but not significantly higher than for patients with a CD4 < 50 cells/μL. For patients with documented treatment failure or default, median time to this outcome was 67.0 days (IQR: 43.0–141.1) for the eight patients (11.8%) with CD4 < 50 cells/μL, 93.0 days (IQR: 63.0–154.0) for the 30 patients (44.1%) with CD4 ≥ 50 cells/μL, and 72.0 days (IQR: 27.5–119.0) for the 30 patients (44.1%) with a missing CD4 cell count. Median time to death of those who died during follow up was 41 days (IQR: 34.0–53.0) for the six patients (10.0%) with CD4 < 50 cells/μL, 55.0 days (IQR: 41.0–99.0) for the 22 (36.7%) with CD4 ≥ 50 cells/μL, and 30.0 days (IQR: 4.0–53.0) for the 32 (53.3%) with a missing CD4 cell count.

Healthcare Worker Perceptions of Barriers to Timely ART Uptake for HIV-Infected TB Patients

Semi-structured interviews were conducted with 333 health care workers to assess their perceptions and current practices of patient referral between TB and HIV programs and facilities (Table 4). Of 312 interviewees that responded to the question on which TB/HIV service delivery model was used in their facility, 125 (40.1%) worked in a facility with an integrated TB/HIV service delivery model. Of 240 respondents, 137 (57.1%) reported having CD4 services available. The preferred mode of referral of patients between HIV and TB services was by escort (40.1%) followed by use of referral slips (38.4%). Most of the staff interviewed (84.4%) reported having TB/HIV guidelines available, however only 59.6% of 285 respondents reported prior training on TB/HIV. Additionally, only 38.8% of 242 respondents reported adhering to recommendations for ART initiation in TB/HIV co-infected patients irrespective of CD4 count, and only 41.9% knew that patients with a CD4 less than 50 cells/μL should start ART within two weeks of TB treatment initiation.

Key recommendations from healthcare worker respondents for improving TB/HIV services for patients ranged from capacity building for health care workers (12.4%), proper patient follow up (19.0%), to patient counseling and health education (38.5%).

4. Discussion

Our study shows that almost 45% of HIV-positive TB patients (55% ART uptake) were not documented to be started on ART before or during their six-month course of TB treatment, despite WHO and Nigerian guideline recommendations. The study participants were selected from DOTS sites across primary, secondary and tertiary health facilities in Ogun State and FCT, Nigeria. This proportion is much higher than the 67% ART uptake reported by WHO for Nigeria within same study period, and also higher than reported elsewhere in sub-Saharan Africa in settings where TB and HIV services were not integrated, WHO TB Report [10–14], Possibly, this could indicate poor documentation of ART initiation in charts in our sampled health facilities, or ART initiated after TB treatment completion. Interviewed healthcare workers in this study also identified poor linkage between TB and HIV services as barrier to timely ART initiation for HIV-positive TB patients. To address this problem, the Nigerian FMOH has since introduced TB/HIV referral coordinators within high volume
ART sites to support referral linkages between DOTS and ART sites so as to improve service uptake among TB and HIV co-infected patients.

The approximately 85% of our HIV-positive TB patients who were not already on ART at the time of TB treatment initiation – if they started ART at all during the course of TB treatment – were not likely to do so within the recommended timeframe. Less than a third of patients with a CD4 ≥50cell/μL started ART within the recommended eight weeks, and only 15% of those with a CD4<50cell/μL started within the recommended two weeks. Almost half of this latter, highly immunocompromised group was not reported to start ART at all during TB treatment, even though the majority of them lived and were followed until successful TB treatment or cure, indicating a window of opportunity to start timely ART that was not prematurely cut short due to loss-to-follow-up or death. This is far behind what has been reported in similar settings in Africa [15–17].

A documented CD4 cell count was missing for 35% of patients. For the more than 40% of health workers interviewed who reported basing their decision to initiate ART on CD4 cell count results, this is problematic. However, this practice is counter to recommended guidelines to begin ART in HIV-positive TB patients irrespective of CD4 cell count, and is likely a major barrier to timely ART uptake. For those that did have a CD4 cell count reported, a CD4 cell count greater or equal to 50cells/μL significantly predicted timely ART, as well as TB treatment completion or cure. The former finding is similar to those from a collaborative analysis of data from South African cohorts, which found that the overall time to starting ART was strongly associated with patient CD4 cell counts [12]. It is important to note that we expected a shorter time to ART initiation for people with lower CD4 counts, and defined “timely ART” differently based on a CD4 cutoff of 50cell/μL; this, while perhaps influencing the likelihood of meeting the expected timeframe, is appropriate based on WHO and Nigerian guidelines. Unfortunately, only 40% of healthcare workers interviewed knew that patients with lower CD4 cell counts should start ART earlier. Clearly, additional training and supportive supervision of health care workers in ART clinics is required.

Overall, almost 70% of co-infected patients had documented TB treatment completion or cure, which reflects the global average [1]. Timely ART initiation relative to TB treatment was not significantly associated with TB treatment outcomes at six months. This has been shown elsewhere, although several randomized controlled trials have demonstrated that early ART improves survival for those with very low CD4 cell counts [5, 6, 18–21]. The odds of a positive TB treatment outcome were, however, more than twice as high for those with CD4 cell counts greater than 50cells/μL than for those with a missing CD4 cell count. Median time to death, treatment failure or default was not significantly different between these groups, indicating that this finding is not simply due to higher rates of death or loss to follow up for those with a missing CD4 cell count.

The key strength of this study was that it assessed routine programmatic data from all types of TB treatment sites, supplemented with in-depth interview with health care workers that provided insights into program challenges and recommendations for improvement. However, some limitations exist. Sites were not nationally representative, patients were not tracked to
non-PEPFAR ART facilities and poor documentation in some facilities led to missing data. We were not able to disaggregate findings based on co-located versus stand-alone TB and HIV facilities, and were only able to follow patients for the six-month duration of their TB treatment course to determine ART uptake.

Overall, this assessment demonstrates unacceptably low levels of timely ART uptake among HIV-positive TB patients in Nigeria, and provides important programmatic feedback to the Nigerian FMOH. Fully integrated TB and HIV service delivery, retraining of staff, ensuring adherence to guidelines recommendations, and interventions to strengthen referral systems should be implemented to ensure timely provision of ART to all HIV-positive TB patients in Nigeria, thus reducing morbidity and mortality and advancing efforts to achieve the ambitious 90-90-90 targets.

Acknowledgments

We thank the health care workers that provided insight into their work and the research assistants that assisted with data collection. We also acknowledge the support we got from the FMOH’s TB and Leprosy Control Program and HIV/AIDS Division, the Ogun State and FCT TB and HIV Control Program staff, and the Institute of Human Virology Nigeria (HVN) TB/HIV team for their leadership and collaboration on this study.

Disclaimer

Funding for the study was made possible by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the United States Centers for Disease Control and Prevention (CDC) or PEPFAR. Use of trade names is for identification only and does not imply endorsement by CDC or the United States Department of Health and Human Services.

References

1. World Health Organization. Global Tuberculosis Report. 2016. http://www.who.int/tb/publications/global_report/en/. Accessed October 20, 2016
2. National Agency for the Control of AIDS. Nigeria Global AIDS Response Progress Report 2015. 2015. http://www.unaids.org/en/regionscountries/countries/nigeria. Accessed June 9, 2016
3. World Health Organization. Policy on Collaborative TB/HIV Activities: Guidelines for National Programs and Other Stakeholders. 2012. http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/. Accessed October 20, 2016
4. Karim SSA, Naidoo K, Grobler A, et al. Integration of Antiretroviral Therapy with Tuberculosis Treatment. N Engl J Med. 2011; 365(16):1492–501. [PubMed: 22010915]
5. Blanc FX, Sok T, Laureillard D, et al. Earlier Versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis. N Engl J Med. 2011; 365(16):1471–81. [PubMed: 22010913]
6. Havlir DV, Kendall MA, Ive P, et al. Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis. N Engl J Med. 2011; 365(16):1482–91. [PubMed: 22010914]
7. The TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373(9):795–807. [PubMed: 26192873]
8. The INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):808–22. [PubMed: 26193126]
9. Nigeria Federal Ministry of Health national Tuberculosis and Leprosy Control Program. Worker’s Manual-Revised. 5th2010. http://www.who.int/hiv/pub/giidelines/nigeria_tb.pdf. Accessed October 20, 2016
10. WHO. Global TB Report. 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf. Accessed 11/12/16
11. Zachariah R, Harries AD, Manzi M, et al. Acceptance of Anti-Retroviral Therapy among Patients Infected with HIV and Tuberculosis in Rural Malawi is Low and Associated with Cost of Transport. PLoS One. 2006; 1(1):e121. [PubMed: 17205125]

12. Lawn SD, Campbell L, Kaplan R, et al. Patients with HIV-Associated Tuberculosis Accessing Non-Integrated Clinical Services in a South African Township. BMC Infect Dis. 2011; 11:258. [PubMed: 21957868]

13. Nglazi MD, Kaplan R, Caldwell J, et al. Antiretroviral Treatment Uptake in Patients with HIV-Associated TB Attending Co-located TB and ART Services. S Afr Med J. 2012; 102(12):936–9. [PubMed: 23498041]

14. Brown, C., Kerschberger, B., Boulle, A., et al. TB and HIV Service Integration within a South African Primary Health Care Setting Reduces the Time to ART Initiation without Negatively Impacting TB Outcomes; Presented at the 18th Conference on Retroviruses and Opportunistic Infections; February 27–Mar 3, 2011; Boston, MA.

15. Owiti P, Zachariah R, Bisseil K, et al. Integrating Tuberculosis and HIV Services in Rural Kenya: Uptake and Outcomes. Public Health Action. 2015; 5(1):36–44. [PubMed: 26400600]

16. Kerschberger B, Hilderbrand K, Boulle AM, et al. The Effect of Complete Integration of HIV and TB Services on Time to Initiation of Antiretroviral Therapy: a Before-After Study. PLoS One. 2012; 7:e46988. [PubMed: 23071690]

17. Tweya H, Ben-Smith A, Kalulu M, et al. Timing of Antiretroviral Therapy and Regimen for HIV-Infected Patients with Tuberculosis: the Effect of Revised Guidelines in Malawi. BMC Public Health. 2014; 14:183. [PubMed: 24555530]

18. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of Antiretroviral Therapy with Tuberculosis Treatment. N Engl J Med. 2011; 365(16):1492–501. [PubMed: 22010915]

19. Takarinda KC, Harries AD, Mutusa-Apollo T, Sandy C, Murimwa T, Mugurungi O. ART Uptake, It’s Timing and Relation to Anti-Tuberculosis Treatment Outcomes Among HIV-Infected TB Patients. Public Health Action. 2012; 2(3):50–5. [PubMed: 26392951]

20. Abay SM, Deribe K, Reda AA, et al. The Effect of Early Initiation of Antiretroviral Therapy in TB/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. J Int Assoc Provid AIDS Care. 2015; 14(6):560–70. [PubMed: 26289343]

21. Naidoo K, Baxter C, Abdool Karim SS. When to Start Antiretroviral Therapy during Tuberculosis Treatment. Curr Opin Infect Dis. 2013; 26(1):35–42. [PubMed: 23188213]
Table 1
Demographic and Clinical Characteristics of Study Participants

| Variable                              | N  | %  |
|---------------------------------------|----|----|
| **Age (N=574)**                       |    |    |
| 15–24                                 | 49 | 8.5|
| 25–34                                 | 183| 31.9|
| 35–44                                 | 216| 37.6|
| 45–54                                 | 96 | 16.7|
| ≥55                                   | 30 | 5.2|
| **Gender (N=569)**                    |    |    |
| Male                                  | 261| 45.9|
| Female                                | 308| 54.1|
| **Baseline CD4 (cells/μL) (N=574)**   |    |    |
| 0–49                                  | 61 | 10.6|
| 50–199                                | 147| 25.6|
| 200–499                               | 141| 24.6|
| ≥500                                  | 26 | 4.5|
| Missing                               | 199| 34.7|
| **TB Facility Type (N=571)**          |    |    |
| Primary                               | 112| 19.6|
| Secondary                             | 318| 55.7|
| Tertiary                              | 141| 24.7|
| **Type of DOT services (N=533)**      |    |    |
| Health facility                       | 351| 65.9|
| Home (treatment supporter)            | 182| 34.1|
| **TB Disease Classification (N=550)** |    |    |
| Pulmonary smear positive              | 246| 44.7|
| Pulmonary smear negative              | 277| 50.4|
| Extra-pulmonary                       | 27 | 4.9|
| **TB Patient Category (N=562)**       |    |    |
| New                                   | 522| 92.9|
| Relapse                               | 11 | 2.0|
| Return after default                  | 3  | 0.5|
| Transfer in                           | 15 | 2.7|
| Prior treatment failure               | 1  | 0.2|
| Other *                               | 10 | 1.8|
| **TB Treatment Outcome (N=558)**      |    |    |
| Cured                                 | 115| 20.6|
| Variable    | N   | %    |
|-------------|-----|------|
| Completed   | 274 | 49.1 |
| Failure     | 6   | 1.1  |
| Default     | 62  | 11.1 |
| Died        | 60  | 10.8 |
| Transfer out| 41  | 7.3  |

*TB patient with unknown previous TB treatment history
## Table 2
Timing of ART Uptake after the Start of TB Treatment Initiation, among Co-infected Patients

| Timing of ART Initiation | CD4 <50 | CD4 >=50 | CD4 Missing | All Patients |
|-------------------------|---------|----------|-------------|--------------|
|                         | N       | % (95% CI)| N           | % (95% CI)   | N           | % (95% CI)   |
| Before TB treatment (Rx)| 7       | 11.5 (0.6–22.3) | 41       | 13.1 (3.3–22.8) | 42       | 21.1 (12.3–29.9) | 90       | 15.7 (7.1–24.2) |
| <2 weeks since TB Rx initiation | 8     | 13.1 (5.2–21.0) | 28       | 8.9 (5.4–12.4) | 19       | 9.5 (5.6–13.5) | 55       | 9.6 (6.9–12.3) |
| 2–8 weeks since TB Rx initiation | 13   | 21.3 (8.7–34.0) | 54       | 17.2 (12.3–22.1) | 21       | 10.6 (4.8–16.3) | 88       | 15.3 (11.2–19.5) |
| >8 weeks since TB Rx initiation | 8     | 13.1 (5.2–21.0) | 560      | 19.1 (11.1–27.1) | 17       | 8.5 (3.9–13.2) | 85       | 14.8 (9.8–19.8) |
| No ART during 6 months TB Rx | 25   | 41.0 (25.9–56.0) | 131      | 41.7 (31.1–52.3) | 100      | 50.3 (37.2–63.3) | 256      | 44.6 (35.9–53.3) |
| **TOTAL**               | 61      | 314      | 199        | 574          |

Univers J Public Health. Author manuscript; available in PMC 2018 June 25.
Table 3

Factors associated with "Timely ART provision to HIV-infected TB patients."

| Variable                  | N (%) | OR (95% CI) | p-value | AOR (95% CI) | p-value |
|---------------------------|-------|-------------|---------|--------------|---------|
| Sex                       |       |             |         |              |         |
| Male                      | 53 (24.8) | 1.29 (0.83–2.00) | 0.2507 | 1.29 (0.83–2.00) | –       |
| Female                    | 54 (20.3) | ref         |         |              |         |
| Age                       |       |             |         |              |         |
| 15–24                     | 7 (17.1) | 0.44 (0.15–1.27) | 0.0220 | 0.68 (0.26–1.78) | 0.0795 |
| 25–34                     | 31 (19.4) | 0.51 (0.24–1.09) |         | 0.59 (0.27–1.29) |         |
| 35–44                     | 37 (21.0) | 0.56 (0.28–1.14) |         | 0.62 (0.31–1.28) |         |
| 45–54                     | 25 (31.7) | 0.98 (0.46–2.10) |         | 1.10 (0.48–2.50) |         |
| ≥55                       | 9 (32.1) | ref         |         |              |         |
| TB Patient Category       |       |             |         |              |         |
| New                       | 104 (23.2) | 1.81 (0.92–3.57) | 0.853 | 1.69 (0.76–3.76) | 0.2011 |
| Other                     | 4 (14.3) | ref         |         |              |         |
| TB Classification         |       |             |         |              |         |
| Pulmonary smear +         | 48 (22.6) | 1.32 (0.36–4.83) | .8448 | –             |         |
| Pulmonary smear –         | 55 (23.7) | 1.40 (0.44–4.45) |         |              |         |
| Extra-pulmonary           | 4 (18.2) | ref         |         |              |         |
| Baseline CD4              |       |             |         |              |         |
| <50/μL                    | 8 (14.8) | ref         |         |              |         |
| 50–199/μL                 | 41 (32.3) | 2.74 (1.41–5.31) |         | 2.67 (1.36–5.22) |         |
| 200–499/μL                | 40 (32.8) | 2.81 (1.31–6.02) |         | 2.74 (1.22–6.15) |         |
| ≥500/μL                   | 1 (4.2) | 0.25 (0.03–1.91) |         | 0.25 (0.03–1.87) |         |
| Missing                   | 19 (12.1) | 0.79 (0.40–1.57) |         | 0.79 (0.39–1.61) |         |
| Type of DOT services      |       |             |         |              |         |
| Health Facility           | 66 (23.0) | 0.98 (0.56–1.74) | .9512 | –             |         |
| Home                      | 38 (23.3) | ref         |         |              |         |
| TB Outcome                |       |             |         |              |         |

Univers J Public Health. Author manuscript; available in PMC 2018 June 25.
| Variable       | N (%)  | OR (95% CI)      | p-value | AOR (95% CI) | p-value |
|---------------|--------|-----------------|---------|--------------|---------|
| Cured or Completed | 82 (24.8) | 1.57 (0.67–3.69) |         |              |         |
| Failure or Default | 8 (15.1)  | 0.85 (0.29–2.46) |         |              |         |
| Transfer out   | 7 (20.0) | 1.19 (0.35–3.69) |         |              |         |
| Died           | 9 (17.3) | ref             |         |              |         |

*Timely ART provision was defined as within two weeks for patients with a CD4 <500 cells/μL or missing, and as within eight weeks for all others.
Table 4
Healthcare Worker Interview Responses (N=333)

| Cadre of Healthcare Staff Interviewed (N=333) | N  | %   |
|-----------------------------------------------|----|-----|
| Doctors                                       | 50 | 15.0|
| Nurse                                         | 108| 32.4|
| Pharmacists                                   | 10 | 3.0 |
| Lab Scientists                                | 13 | 3.9 |
| Community Health Workers                      | 100| 30.0|
| Medical Records staff                         | 15 | 4.5 |
| Counsellors                                   | 16 | 4.8 |
| Others                                        | 21 | 6.3 |

Reported Facility Characteristics

| Has TB diagnostic services (AFB) available (N=178) | 175 | 98.3 |
| TB/HIV service delivery model (N=312)             |     |     |
| Stand-alone TB facility                            | 133 | 42.6|
| Stand-alone ART facility                           | 54  | 17.3|
| Integrated TB/HIV facility                         | 125 | 40.1|
| CD4 available at site (N=240)                      | 137 | 57.1|

| Distance to referral site for TB diagnosis (n = 136) |     |     |
| Less than 5 Km                                      | 56  | 41.2|
| 6–10 Km                                             | 39  | 28.7|
| 10–20 Km                                            | 29  | 21.3|
| Over 20 Km                                          | 12  | 8.8 |

| Method of TB patient referral for HIV services (N= 232) |     |     |
| Physical escort                                      | 93  | 40.1|
| Referral slip/directed to ART site                   | 89  | 38.4|
| Given an appointment                                 | 19  | 8.2 |
| Don’t know/other                                     | 31  | 13.4|

Healthcare Worker TB/HIV Knowledge and Management

| Reports past training on TB/HIV (N=285)               | 170 | 59.6|
| Reports past training on HIV testing for TB patients (N=207) | 191 | 92.2|
| Reports available TB/HIV guidelines (N= 282)          | 238 | 84.4|
| Reports available guidelines on HIV testing for TB patients (N=282) | 238 | 84.4|

Identification of PLHIV for TB evaluation (N=265)
| Question                                                                 | N   | %   |
|-------------------------------------------------------------------------|-----|-----|
| Every patient                                                           | 83  | 31.2|
| Presumptive TB patients only                                            | 139 | 52.5|
| Don’t know/other                                                        | 43  | 16.2|
| Total                                                                   | 264 |     |
| Asks adult TB patients about child contacts                           | 249 | 94.3|
| Interpretation of guidelines for ART in TB/HIV patients               |     |     |
| ART initiation based on CD4                                            | 101 | 41.7|
| ART initiation irrespective of CD4                                     | 94  | 38.8|
| Don’t know/other                                                        | 47  | 19.4|
| Interpretation of guidelines for patients with CD4<50                 |     |     |
| Immediate within 2 weeks                                               | 99  | 41.9|
| Deferment till after 2 months of TB Rx                                 | 39  | 16.5|
| Initiation based on clinical judgement                                 | 39  | 16.5|
| Don’t know/Other                                                        | 59  | 25.0|
| Opinion on how to improve TB case detection                            |     |     |
| Implement active TB case finding                                       | 155 | 45.7|
| Improve on TB contact tracing                                          | 9   | 2.7 |
| Opinion on how to ensure TB/HIV patients enroll in care               |     |     |
| Practice same day enrollment                                           | 133 | 60.2|
| Don’t know/Other                                                        | 88  | 39.8|
| Opinion on how to ensure ART started within 8 weeks                    |     |     |
| Given appointment at start of TB                                       | 86  | 40.0|
| Use of reminders                                                        | 30  | 14.0|
| Tracked home on missed appointment                                    | 37  | 17.2|
| Don’t know/Other                                                        | 62  | 28.8|
| Opinion on how to ensure TB/HIV patients remain on ART                 |     |     |
| Provide adherence support                                              | 141 | 65.3|
| Use of treatment supporter                                              | 23  | 10.6|
| Don’t know                                                             | 39  | 18.1|
| Other methods                                                           | 24  | 11.1|
| Recommendations for service improvement                               |     |     |
| Referral/proper patient follow up                                      | 43  | 19.0|
| Counseling and health education                                        | 87  | 38.5|
| Campaign and awareness                                                 | 3   | 1.3 |
| Capacity building for HCWs                                              | 28  | 12.4|
| Establishment of same site services                                    | 5   | 2.2 |
| Mixed responses of the above and others                                | 64  | 28.3|